Pzena Investment Management LLC Sells 78,159 Shares of USANA Health Sciences, Inc. $USNA

Pzena Investment Management LLC lessened its holdings in USANA Health Sciences, Inc. (NYSE:USNA) by 6.4% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 1,134,429 shares of the company’s stock after selling 78,159 shares during the period. Pzena Investment Management LLC owned 0.06% of USANA Health Sciences worth $22,269,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also added to or reduced their stakes in the company. National Bank of Canada FI raised its stake in USANA Health Sciences by 166.6% in the 3rd quarter. National Bank of Canada FI now owns 1,922 shares of the company’s stock valued at $53,000 after acquiring an additional 1,201 shares during the period. Tower Research Capital LLC TRC raised its stake in USANA Health Sciences by 382.5% in the 2nd quarter. Tower Research Capital LLC TRC now owns 2,398 shares of the company’s stock valued at $73,000 after acquiring an additional 1,901 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in USANA Health Sciences by 52.9% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,834 shares of the company’s stock valued at $106,000 after acquiring an additional 1,327 shares during the period. Quantbot Technologies LP raised its stake in USANA Health Sciences by 19.5% in the 2nd quarter. Quantbot Technologies LP now owns 3,957 shares of the company’s stock valued at $121,000 after acquiring an additional 646 shares during the period. Finally, iSAM Funds UK Ltd bought a new stake in USANA Health Sciences in the 3rd quarter valued at $120,000. Institutional investors own 54.25% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on USNA shares. Weiss Ratings restated a “sell (d)” rating on shares of USANA Health Sciences in a research note on Friday, March 27th. Zacks Research cut USANA Health Sciences from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, April 22nd. Finally, Wall Street Zen cut USANA Health Sciences from a “buy” rating to a “hold” rating in a research note on Saturday, May 2nd. One equities research analyst has rated the stock with a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Reduce”.

Insiders Place Their Bets

In other USANA Health Sciences news, insider Joshua Foukas sold 3,791 shares of the stock in a transaction on Thursday, May 7th. The stock was sold at an average price of $19.82, for a total transaction of $75,137.62. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 0.82% of the stock is owned by insiders.

USANA Health Sciences Price Performance

USNA stock opened at $18.66 on Friday. The stock has a market capitalization of $344.46 million, a price-to-earnings ratio of 39.70, a PEG ratio of 0.71 and a beta of 0.77. The business’s fifty day moving average price is $18.16 and its two-hundred day moving average price is $19.52. USANA Health Sciences, Inc. has a fifty-two week low of $16.60 and a fifty-two week high of $38.32.

USANA Health Sciences (NYSE:USNA) last posted its quarterly earnings data on Tuesday, May 5th. The company reported $0.61 earnings per share for the quarter, topping the consensus estimate of $0.44 by $0.17. The firm had revenue of $250.22 million for the quarter, compared to analysts’ expectations of $240.99 million. USANA Health Sciences had a return on equity of 6.21% and a net margin of 0.96%.USANA Health Sciences has set its FY 2026 guidance at 1.950-2.290 EPS. Research analysts expect that USANA Health Sciences, Inc. will post 2.12 EPS for the current year.

USANA Health Sciences Profile

USANA Health Sciences, Inc is a Utah‐based company that develops, manufactures and distributes nutritional supplements and personal care products through a network of independent distributors. Founded in 1992 by Dr. Myron Wentz, the company’s portfolio includes vitamins, minerals, dietary supplements, weight‐management products and skin‐care formulations. USANA’s products are formulated in its own laboratories to meet pharmaceutical‐grade standards, and the company has invested heavily in research and development and quality control to support its offerings.

Operating primarily through a direct selling model, USANA serves markets in North America, Asia Pacific, Europe and Latin America.